Compare DexCom, Inc. (DXCM) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Unilever plc — how do they compare? DexCom, Inc. trades at $77.28 (market cap $28.06B), while Unilever plc trades at $62.63 (market cap $129.57B). The key difference: Unilever plc is far larger — about 4.6× DexCom, Inc.'s market cap, and Unilever plc pays a 3.71% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | UL | |
|---|---|---|
Market Cap | $28.06B | $129.57B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $74.59 |
52-Week Low | $54.84 | $55.05 |
Enterprise Value | $27.03B | $155.02B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Unilever (UL) trades at $62.49, up 2.71% with a bullish technical signal. Recent earnings misses contrast with strong profitability margins and a 53.32% ROE. The company is divesting its food business to McCormick and investing in innovation, while maintaining a $0.54 dividend. Cash flow improved to $1.91B net in 2024 after a volatile period.
Outlook remains mixed: valuation appears fair with a P/E of 20.83, but revenue declines and execution risks on strategic deals pose challenges. Analyst sentiment is cautious with only 24% buy ratings. The stock offers stability through dividends but faces headwinds in sales growth and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
